📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
HOME › COVERAGE › TSHA › NEWS
NEWS HUB
News Coverage Earnings Hub Earnings Report Grades
$TSHA
1 articles in last 30 days
LAST 30 DAYS
1 articles
AVG GRADE
NEUTRAL
score: 0.00
SENTIMENT
NEUTRAL
TOTAL VIEWS
16

TSHA Latest News & AI Sentiment Analysis

1 articles · Grade: NEUTRAL · Real-time AI-graded coverage
RECENT COVERAGE · 6 ARTICLES
finance.yahoo.com · 14:01 · 07/15 LOW NEUTRAL
Taysha Gene Therapies (TSHA) is One of The Most Affordable Biotech Names to Invest In
Taysha Gene Therapies (TSHA) announced a public equity offering of 32.5 million shares at $6 per share, along with warrant components,...
manilatimes.net · 02:43 · 06/25 NEUTRAL NEUTRAL
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Taysha Gene Therapies (TSHA) announced pricing for a substantial equity offering, issuing 32.5 million shares at $6.00 per share...
seekingalpha.com · 20:25 · 06/24 NEUTRAL BEARISH
Taysha Gene Therapies launches $200M public offering; shares down (NASDAQ:TSHA)
TSHA initiated a $200M capital raise via equity and warrant offering, a typical financing mechanism for clinical-stage or...
manilatimes.net · 20:21 · 06/24 NEUTRAL NEUTRAL
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Taysha Gene Therapies (TSHA) announced a $200 million underwritten public offering of common stock and pre-funded warrants, a routine...
seekingalpha.com · 17:31 · 06/23 NEUTRAL NEUTRAL
Taysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome - Slideshow (NASDAQ:TSHA) 2026-06-23
Taysha Gene Therapies (TSHA) released updated clinical data and program information for TSHA-102, its candidate therapy targeting Rett...
seekingalpha.com · 20:42 · 06/22 NEUTRAL NEUTRAL
Taysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome Transcript
Taysha Gene Therapies (TSHA) released longer-term clinical data and a program update for TSHA-102, a gene therapy candidate targeting...
NEWS-BASED SECTOR EXPOSURE ANALYSISPOWERED BY CLAUDE HAIKU 4.5NOT INVESTMENT ADVICE
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours. Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice